{"id":"W2971538989","doi":"10.1053/j.gastro.2019.08.043","title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis","year":2019,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":221,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Genentech; Atlantic Healthcare; Ferring Pharmaceuticals; Otsuka America; Ipsen Biopharmaceuticals; Celgene; Novo Nordisk; Teva Pharmaceutical Industries; EA Pharma Co., Ltd.; Gilead Sciences; AbbVie; Merck; Sanofi; Takeda Pharmaceuticals U.S.A.; Tillotts Pharma; Hospira; Amgen; Pfizer; Shire; Eli Lilly and Company","keywords":"Ulcerative colitis; Medicine; Randomized controlled trial; Internal medicine; Gastroenterology; Phase (matter); Colitis; Chemistry; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00414646,0.001531701,0.002920617,0.0004088953,0.000602448,0.0009244464,0.000610801,0.001552471,0.004891418],"category_scores_gemma":[0.002560439,0.0009457952,0.001888582,0.0003823987,0.001115808,0.001093209,0.0004845956,0.002766673,0.0008077964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006081371,"about_ca_system_score_gemma":0.001445208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003843144,"about_ca_topic_score_gemma":0.0009980663,"domain_scores_codex":[0.9984204,0.001026507,0.00008778535,0.0002156917,0.0001090489,0.0001405764],"domain_scores_gemma":[0.9983597,0.0003438347,0.0004199877,0.000138271,0.0001453672,0.000592802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9653197,0.01341807,0.003012977,0.0003080547,0.0009642899,0.00005944745,0.00007128424,0.0002133786,0.003706654,0.00004705682,0.0007000518,0.01217888],"study_design_scores_gemma":[0.9014773,0.09198887,0.004960047,0.00001622237,0.0003897911,0.00004771955,0.00001556274,0.0002338033,0.0002882161,0.00005579316,0.00051598,0.00001075868],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884918,0.003030569,0.0005028383,0.0007518968,0.0002940312,0.004846934,0.000710186,0.00006676837,0.001305101],"genre_scores_gemma":[0.9838914,0.00186115,0.001919666,0.001385607,0.0004806157,0.007455506,0.001149797,0.00002283991,0.001833358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004891418,"threshold_uncertainty_score":0.02192885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003221125034903623,"score_gpt":0.226143267694216,"score_spread":0.2229221426593123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}